Rosuvastatin for Primary Prevention in Older Individuals With High C-Reactive Protein and Low LDL (JUPITER Analysis)

This analysis of the JUPITER trial asked whether statins help older adults who, by conventional cholesterol criteria, would not qualify for treatment — they had normal LDL but elevated inflammation (hs-CRP).

In adults aged 70 and over with this profile, rosuvastatin cut major cardiovascular events by 39 percent, and because older people have higher baseline risk, the absolute benefit was actually larger than in younger participants. The finding supports treating high-risk older adults identified by inflammation rather than by LDL alone, and counters the assumption that statins are less worthwhile with age.

The caveats: this is a subgroup analysis of a trial (JUPITER) that selected patients by elevated hs-CRP, so the population is specific, and exploratory subgroup results carry less weight than primary findings. The role of hs-CRP as a treatment trigger also remains debated.

We rate the evidence moderate-to-strong. It is a secondary analysis of a major randomized trial, usefully suggesting that older adults with inflammatory risk benefit from statins, while inheriting the interpretive limits of subgroup and CRP-selected analyses.